Home > Insider Trading > Filing (0000899243-20-010119)

Filing Details

Accession Number:: 0000899243-20-010119
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-04-03 16:10:23
Reporting Period:: 2020-04-01

Accepted Time:: 2020-04-03 16:10:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1743881	Bridgebio Pharma Inc.	BBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1742485	Neil Kumar	C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-04-01	27,719	$25.52	2,617,653	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-04-01	20,040	$26.38	2,597,613	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-04-01	12,976	$27.45	2,584,637	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-04-01	1,382	$28.20	2,583,255	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-04-02	15,778	$25.04	2,567,477	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,685,725	Direct
Common Stock	927,686	Indirect	See footnote

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019.
Represents the weighted average sale price of the shares sold from $25.00 to $25.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7.
The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Represents the weighted average sale price of the shares sold from $26.00 to $26.94 per share.
Represents the weighted average sale price of the shares sold from $27.00 to $27.99 per share.
Represents the weighted average sale price of the shares sold from $28.01 to $28.47 per share.
Represents the weighted average sale price of the shares sold from $25.00 to $25.30 per share.
The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.